medigraphic.com
ISSN 2007-2783 (Print)
Órgano Oficial del Instituto Científico Pfizer

2020, Number 1

<< Back Next >>

Residente 2020; 15 (1)

Infections associated with the use of anti-TNF drugs in rheumatic diseases

Cruz-López G, Muñoz-Montes de Oca DL, Torres-Monarrez A, Rubio-Castro JJ, Anaya-Ambriz EJ, Echeverría-González G, Ponce-Guarneros JM, Nava-Valdivia CA

Language: Spanish
References: 47
Page: 12-18
PDF size: 259.13 Kb.


ABSTRACT

Tumor necrosis factor alpha (TNF-α) is a fundamental proinflammatory cytokine in the response of the immune system against infections, in addition to participating in the inflammatory pathogenesis of chronic diseases of autoimmune origin. Antibody-based biological therapies targeting TNF-α are a valuable resource in the treatment of rheumatic diseases. However, this leads to an increased susceptibility to infections with opportunistic pathogens and complications in these patients. The objective of this review is to report evidence on the main infections registered after the use of anti-TNF-α therapies in patients with rheumatic diseases, as well as the strategies carried out in these cases.


REFERENCES

  1. Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology. 2005; 115 (1): 1-20.

  2. Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R et al. Reduction of chemokine levels and leucocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. 2000; 43 (1): 38-47.

  3. Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Ishida H et al. Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF-alpha antibody therapy. J Clin Immunol. 1999; 19 (5): 305-313.

  4. Murdaca G, Spanò F, Contatore M, Guastalla A, Penza E, Magnani O, Puppo F. Infection risk associated with anti-TNF-α agents: a review. Expert Opin Drug Saf. 2015; 14 (4): 571-582.

  5. Thalayasingam N, Isaacs J. Anti-TNF therapy. Best Pract Res Clin Rheumatol. 2011; 25 (4): 549-567.

  6. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol. 2006; 2 (11): 602-610.

  7. Rodrígez-Lozano C. Safety of biological therapies: new data from BIOBADASER. Reumatol Clin. 2011; 6S3: S1-6.

  8. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006; 54 (8): 2368-2376.

  9. Tufariello JM, Chan J, Flynn JL. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis. 2003; 3 (9): 578-590.

  10. Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol. 2002; 168 (9): 4620-4627.

  11. Kapoor N, Pawar S, Sirakova TD, Deb C, Warren WL, Kolattukudy PE. Human granuloma in vitro model, for TB dormancy and resuscitation. PLoS ONE. 2013; 8 (1): e53657.

  12. Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002; 46 (9): 2287-2293.

  13. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, Kampmann B et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010; 36 (5): 1185-1206.

  14. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004; 38 (9): 1261-1265.

  15. Fernández-Ruiz M, Aguado JM. Risk of infection associated with anti-TNF-alpha therapy. Expert Rev Anti Infect Ther. 2018; 16 (12): 939-956.

  16. Goletti D, Petrone L, Ippolito G, Niccoli L, Nannini C, Cantini F. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. Expert Rev Anti Infect Ther. 2018; 16 (6): 501-512.

  17. Diederen BM. Legionella spp and Legionnaires disease. J Infect. 2008; 56 (1): 1-12.

  18. Kawamoto Y, Morinaga Y, Kimura Y, Kaku N, Kosai K, Uno N et al. TNF-α inhibits the growth of Legionella pneumophila in airway epithelial cells by inducing apoptosis. J Infect Chemother. 2017; 23 (1): 51-55.

  19. Silver Spring, MD: US Food and Drug Administration. (2011). FDA drug safety communication: Drug labels for tumor necrosis factor-alpha (TNFα) blockers now include warnings about infections with Legionella and Listeria bacteria.

  20. Pillich H, Chakraborty T, Mraheil MA. Cell-autonomous responses in Listeria monocytogenes infection. Future Microbiol. 2015; 10 (4): 583-597.

  21. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003; 48 (2): 319-324.

  22. Schett G, Herak P, Graninger W, Smolen JS, Aringer M. Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature. J Clin Microbiol. 2005; 43: 2537-2541.

  23. Kesteman T, Yombi JC, Gigi J, Durez P. Listeria infections associated with infliximab: case reports. Clin Rheumatol. 2007; 26 (12): 2173-2175.

  24. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor antagonists infliximab and etanercept. Arthritis Rheum 2002; 46: 2565-2570.

  25. Aikawa NE, Rosa DT, Del Negro GM, Moraes JC, Ribeiro AC, Gonçalves SC et al. Systemic and localized infection by Candida species in patients with rheumatic diseases receiving anti-TNF therapy. Rev Bras Reumatol. 2016; 56 (6): 478-482.

  26. Tanaka M, Sakai R, Koike R, Komano Y, Nanki T, Sakai F et al. Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors. Mod Rheumatol. 2012; 22 (6): 849-858.

  27. Murdaca G, Negrini S, Pellecchio M, Greco M, Schiavi C, Giusti F et al. Update upon the infection risk in patients receiving TNF alpha inhibitors. Expert Opin Drug Saf. 2019; 18 (3): 219-229.

  28. Van der Klooster JM, Bosman RJ, Oudemans-van Straaten HM, Van der Spoel JI, Wester JP, Zandstra DF. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med. 2003; 29 (12): 2327-2329.

  29. Justice EA, Khan SY, Logan S, Jobanputra P. Disseminated cutaneous herpes simplex virus-1 in a woman with rheumatoid arthritis receiving infliximab: a case report. J Med Case Rep. 2008; 2: 282.

  30. Schepers K, Hernandez A, Andrei G, Gillemot S, Fiten P, Opdenakker G et al. Acyclovir-resistant herpes simplex encephalitis in a patient treated with anti-tumor necrosis factor-α monoclonal antibodies. J Clin Virol. 2014; 59 (1): 67-70.

  31. Nordgaard-Lassen I, Frederik DJ, Belard E, Gerstoft J, Kjeldsen J, Kragballe K et al. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J. 2012; 59 (7): 4480.

  32. Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013; 309 (9): 887-895.

  33. García-Doval I, Pérez-Zafrilla B, Descalzo MA, Roselló R, Hernández MV, Gómez-Reino JJ et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis. 2010; 69 (10): 1751-1715.

  34. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. JAMA. 2009; 301 (7): 737-744.

  35. Che H, Lukas C, Morel J, Combe B. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine. 2014; 81 (3): 215-212.

  36. Liao TL, Chen YM, Liu HJ, Chen DY. Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia. BMJ Open. 2017; 7 (1): e014032.

  37. Nicolai R, Cortis E, Ravà L, Bracaglia C, Pardeo M, Insalaco A et al. Herpes virus infections during treatment with etanercept in juvenile idiopathic arthritis. Pediatric Infect Dis Soc. 2015; 5 (1): 76-79.

  38. Rubin LG, Levin MJ, Ljungman P, Graham DE, Avery R, Tomblyn M et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014; 58 (3): 309-318.

  39. Domm S, Cinatl J, Mrowietz U. The impact of treatment with tumour necrosis factor-α antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol. 2008; 159 (6): 1217-1228.

  40. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still’s disease. J Rheumatol. 2003; 30 (7): 1624-1625.

  41. Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlotsky JM et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol. 2004; 31 (1): 107-109.

  42. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis. 2003; 62 (7): 6867.

  43. Zylberberg H, Rimaniol AC, Pol S, Masson A, De Groote D, Berthelot P et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol. 1999; 30 (2): 185-191.

  44. Fukuda R, Ishimura N, Ishihara S, Chowdhury A, Morlyama N, Nogami C et al. Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C. Liver. 1996; 16 (6): 390-399.

  45. Maurice MM, Van der Graaff WL, Leow A, Breedveld FC, Van Lier RA, Verweij CL. Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th 1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum. 1999; 42 (10): 2166-2173.

  46. Berg L, Lampa J, Rogberg S, Van Vollenhoven R, Klareskog L. Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors. Ann Rheum Dis. 2001; 60 (2): 133-139.

  47. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis. 2004; 63 (2): 18-24.




2020     |     www.medigraphic.com